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that has demonstrated the efﬁcacy of PEG-IFN alfa-2b plus
weight-based ribavirin in patients with chronic hepatitis C and
signiﬁcant ﬁbrosis who previously failed any interferon–alfa/
ribavirin therapy. The aim of the present study was to assess
FibroTest (FT), a validated non-invasive marker of ﬁbrosis in
treatment-naive patients, as a possible alternative to biopsy as
the baseline predictor of subsequent early virologic (EVR) and
sustained virologic response (SVR) in previously treated patients.Journal of Hepatology 20
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weight-based dose.line FT, biopsy, and complete data. Uni- (UV) and multi-variable
(MV) analyses were performed using FT and biopsy.
Results: Baseline characteristics were similar as in the overall
population; METAVIR stage: 28% F2, 29% F3, and 43% F4, previous
relapsers 29%, previous PEG-IFN regimen 41%, high baseline viral
load (BVL) 64%. 506 patients (35%) had undetectable HCV-RNA at
TW12 (TW12neg), with 58% achieving SVR. The accuracy of FT
was similar to that in naive patients: AUROC curve for the diagno-
sis of F4 vs F2 = 0.80 (p <0.00001). Five baseline factors were asso-
ciated (p <0.001) with SVR in UV andMV analyses (odds ratio: UV/
MV): ﬁbrosis stage estimated using FT (4.5/5.9) or biopsy (1.5/
1.6), genotype 2/3 (4.5/5.1), BVL (1.5/1.3), prior relapse (1.6/1.6),
previous treatment with non-PEG-IFN (2.6/2.0). These same fac-
tors were associated (p 60.001) with EVR. Among patients
TW12neg, two independent factors remained highly predictive
of SVR by MV analysis (p 60.001): genotype 2/3 (odds ratio = 2.9),
ﬁbrosis estimated with FT (4.3) or by biopsy (1.5).
Conclusions: FibroTest at baseline is a possible non-invasive
alternative to biopsy for the prediction of EVR at 12 weeks and
SVR, in patients with previous failures and advanced ﬁbrosis,
retreated with PEG-IFN alfa-2b and ribavirin.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Introduction
The assessment of ﬁbrosis stage is useful in the treatment of
patients with chronic hepatitis C (CHC), both for the decision to
treat and in follow-up [1]. Because of the potentially untoward11 vol. 54 j 227–235
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complications of liver biopsy, several non-invasive methods have
been developed as possible alternatives [2].
FibroTest (FT), a set of non-invasive biomarkers of liver ﬁbro-
sis and activity, has been extensively validated in patients with
CHC [2,3]; with similar diagnostic and prognostic value as a
biopsy of 25-mm length [4,5], FT has been approved by the health
authority in France as a possible alternative for the initial assess-
ment of ﬁbrosis and cirrhosis in patients with CHC[6,7].
Several studies of FT during standard hepatitis C virus (HCV)
treatment in treatment-naive patients have been performed.
These studies demonstrated that FT is similar to paired liver biop-
sies in demonstrating reduced necrosis and ﬁbrosis in sustained
virologic responders [5,8–11]. However, no speciﬁc study of FT
has been performed in previous non-responders to interferon/
ribavirin treatment.
The aim of this analysis was to validate the utility of FT as a
possible alternative to biopsy for staging ﬁbrosis in non-respond-
ers using the ﬁrst phase of the EPIC-3 trial (Evaluation of PegIn-
tron in Control of Hepatitis C Cirrhosis) – a large, prospective,
multiphase clinical program – evaluating the retreatment of
patients with CHC with signiﬁcant ﬁbrosis/cirrhosis in whom
previous treatment with non-pegylated or peginterferon (PEG-
IFN) alfa plus ribavirin was ineffective (i.e., virologic non-
responders or relapsers) [12].Patients and methods
Patient selection
Patients enrolled in EPIC3 were included in the present FT evaluation if they had
12 weeks of virology (TW12) results available, interpretable baseline FT and liver
biopsy. Details of inclusion criteria aswell as the results of the ﬁrst study of the pro-
gramhave been published elsewhere. Twelve patients 18–65 years of agewith CHC
and signiﬁcant hepatic ﬁbrosis/cirrhosis (METAVIR score F2, F3, or F4), who failed
combination therapy with non-pegylated or PEG-IFN alfa/ribavirin therapy, were
eligible to enroll. All patients in this study had previously received a minimum of
12 weeks of combination therapy and did not achieve sustained virologic response
(SVR). Patients were categorized according to the previous response (non-respon-
der, relapser, or treatment failure) to combination therapy based on documented
HCV-RNA polymerase chain reaction (PCR) results. Non-responders had detectable
HCV-RNA at the end of therapy. Relapsers had undetectable HCV-RNA at the end of
treatment (EOT) and had subsequent detectable HCV-RNA during post-treatment
follow-up. Patients, who did not meet the protocol deﬁnition for non-responder
or relapser because documentation of HCV-RNA assays did not fulﬁll these deﬁni-
tions but had detectable HCV-RNAmore than 1 week after the end of their previous
therapeutic regimen, were designated as treatment failures. These patients likely
represented amixture of relapsers and non-responders. Additionalmajor inclusion
criteria were HCV-RNA positivity, hepatic ﬁbrosis documented by historical biopsy
showing at least portal ﬁbrosis with few septa (METAVIR score F2), compensated
liver disease (Child-Pugh class A), hemoglobin P12 g/dl for women and P13 g/
dl for men, absolute neutrophil countP1500/mm3, platelet countP80,000/mm3
and body weight of 40–125 kg. Major exclusion criteria included known coinfec-
tion with HIV or hepatitis B virus, decompensated liver disease and history of or
current hepatocellular carcinoma.
Study design and conduct
The retreatment trial of the EPIC-3 program is a prospective, open-label, clinical
trial and was conducted at 133 sites in North America, Europe, Latin America, Tai-
wan and Australia. Patients received PEG-IFN alfa-2b 1.5 lg/kg/wk and daily
weight-based dose (WBD) ribavirin (800 mg for 665 kg; 1000 mg for >65–
85 kg; 1200 mg for >85–105 kg; and 1400 mg for >105–125 kg) for up to
48 weeks. Patients with detectable HCV-RNA at treatment week (TW) 12 were
offered randomization into maintenance studies. The study was approved by
the ethics committee at each participating institution and was conducted accord-
ing to good clinical practice and the Declaration of Helsinki. All patients provided
written informed consent [12].228 Journal of Hepatology 201Assessments
Serum samples and biochemical markers
FibroTest was measured at screening. Serum samples were collected and cen-
trally stored. Samples were blindly assessed without knowledge of any patient
characteristics and according to recommended procedures [3,13–15]. FT com-
bined the following ﬁve markers: alpha2-macroglobulin, haptoglobin, gamma
glutamyl transpeptidase (GGT), total bilirubin, and apolipoprotein A1. Apolipo-
protein A1, alpha2-macroglobulin, and haptoglobin were determined using
serum samples stored at 80 C. An automatic nephelometer (Beckman Instru-
ments, Brea, CA, USA, or Dade-Behring, Deerﬁeld, IL, USA) and Roche Diagnostics
reagents (Roche Diagnostics, Indianapolis, IN, USA), Siemens Healthcare Diagnos-
tics reagents (Siemens Healthcare Diagnostics, Deerﬁeld, IL, USA), or Beckman
Instruments reagents (Beckman Instruments, Brea, CA, USA) were used. The coef-
ﬁcient of variation of all assays was lower than 3%. GGT, alanine aminotransferase
(ALT), and total bilirubin were assessed prospectively during the trial period,
using Hitachi 747 or 911 automates or Roche Modular Analysers.
ActiTest (AT) combined the same ﬁve markers as FT plus ALT. It has a high
predictive value for the diagnosis of signiﬁcant activity features [3,14]. SteatoTest
combines the same 6 markers as AT plus aspartate aminotransferase (AST), serum
triglycerides, cholesterol, fasting glucose and body mass index. It has a high pre-
dictive value for the diagnosis of signiﬁcant steatosis [16].
Virologic markers
Plasma HCV-RNA was measured at screening, at weeks 12, 24, and 48 of treat-
ment and at 12 and 24 weeks post-treatment. HCV-RNA analyses (TaqMan;
Applied Biosystems, Foster City, CA, USA; lower limit of detection [LLD] for 95%
sensitivity of 125 IU/ml) were performed centrally at the Schering-Plough
Research Institute (SPRI) Laboratory (Kenilworth, NJ, USA). Samples below the
LLD for which a signal was detected were characterized as low positive or detect-
able; those for which no signal was detected were characterized as negative or
undetectable. Conﬁrmatory testing using TaqMan (Quest Nichols Laboratory,
San Juan Capistrano, CA, USA) was performed on a subset of samples tested at
the SPRI Laboratory. Early virologic response (EVR) was deﬁned as HCV-RNA
below the LLD (125 IU/ml) at TW12. The primary efﬁcacy end point of the thera-
peutic study was SVR, deﬁned as undetectable serum HCV-RNA 24 weeks post-
treatment. A secondary efﬁcacy end point was the difference in SVR rates by
ﬁbrosis score.
Histological criteria
Pretreatment liver biopsy specimens were scored by a single pathologist using
METAVIR criteria [17]. The pathologist was blinded to historical biopsy reports
and other clinical data. All the patients were biopsied after their prior failed ther-
apeutic regimen.
Statistical analysis
Calculating FibroTest diagnostic values
The diagnostic values of FT were assessed by the receiver-operating characteris-
tics (ROC) curves, which plot sensitivity versus 1 – speciﬁcity [14,18–19]. The
respective overall diagnostic values were compared using the area under the
ROC curves (AUROCs). The AUROCs were compared to 0.50 (no diagnostic value)
and to AUROCs observed in an integrated database of patients with CHC who
were never treated (naive population) [14].
Estimates of AUROCs and comparisons between AUROCs used an empirical
nonparametric method [18,19]. Two factors are strongly associated with the AUR-
OCs of ﬁbrosis biomarkers and biopsy: the prevalence of the different ﬁbrosis
stages that deﬁne advanced and non-advanced ﬁbrosis [20,21] and the length
of biopsy [21,22].
To address this risk of spectrum bias due to different prevalences of ﬁbrosis
stages between studies we used two previously validated method of standardiza-
tion [20–22]. For the same test, if only F3 and F4 patients are included, AUROCs
are mathematically lower than if only F2 and F4 patients are included [20,23].
Using an equal proportion of each ﬁbrosis stage permitted a standardized AUROC
expression. In this standard prevalence distribution, the difference between the
mean ﬁbrosis stage of advanced ﬁbrosis minus the mean ﬁbrosis stage of non-
advanced ﬁbrosis (DANA) is 2.5. The ﬁrst step of such a standardization is to
estimate the relationship between DANA and observed AUROCs (ObAUROC).
For each population, DANA is calculated as: mean advanced ﬁbrosis estimated
by {[(prevalence F2  2) + (prevalence F3  3) + (prevalence F4  4)]/(prevalence
F2 + prevalence F3 + prevalence F4)} minus mean non-advanced ﬁbrosis esti-
mated by [prevalence F1/(prevalence F0 + prevalence F1)]. From the regression
formula linking the ObAUROC to DANA, one can calculate an AUROC standardized1 vol. 54 j 227–235
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(StAUROC) at the DANA value of 2.5. Contrary to the ObAUROC, the StAUROC esti-
mate for a given test for the diagnosis of advanced ﬁbrosis is independent of the
prevalence of advanced (F4) and non-advanced ﬁbrosis (F2/F3) stages. We used
the previously validated formula in patients with CHC [StAUROC = ObAUROC +
(0.1056) (2.5  ObDANA)]. The corresponding StAUROC for F2 versus F4
(ObDANA = 2) was ObAUROC + (0.1056)(0.5) = ObAUROC + 0.0528. The corre-
sponding StAUROC for F2 versus F3 (ObDANA = 1) was ObAUROC +
(0.1056)(1.5) = ObAUROC + 0.1584.
To prevent the risk of considering a short biopsy sample as the gold stan-
dard, we used the previously validated adjusted FT AUROC as the gold standard
for the given biopsy length (AlAUROC) [21] For instance a biopsy of 16-mm
length for the diagnosis of F3 versus F4 has an AUROC of 0.82 versus the gold
standard (entire liver) (GsAUROC). The FibroTest AlAUROC = ObAUROC/GsAU-
ROC. An ObAUROC for FT of 0.71, using biopsy of 16 mm, has an
A1AUROC = 0.71/0.82 = 0.87.22.
Obuchowski measure
Lambert et al. proposed in order to overcome both spectrum effect and ordinal
scale, to use the Obuchowski measure [21]. Furthermore this measure allows to
compare two biomarkers with a single test, avoiding appropriate correction for
the type I error when comparing two biomarkers for different stages or grades.
This measure is a multinomial version of the AUROC. With N categories of the
gold standard outcome (histological ﬁbrosis stage) and AUROCst, the estimate
of the AUROC of diagnostic tests for differentiating between categories s and t,
the Obuchowski measure, is a weighted average of the N(N  1)/2 different
AUROCst corresponding to all the pairwise comparisons between two of the N
categories. Each pairwise comparison has been weighted to take into account
the distance between ﬁbrosis stages (i.e., the number of units on the ordinal
scale). A penalty function proportional to the difference in METAVIR units
between Stages was deﬁned: the penalty function was 0.25 when the difference
between stages was 1, 0.50 when the difference was 2, and 1 when the difference
was 3. The Obuchowski measure can be interpreted as the probability that the
non-invasive index will correctly rank 2 randomly chosen patient samples from
different ﬁbrosis stages according to the weighting scheme, with a penalty for
misclassifying patients [21].
Prognostic value of FibroTest
Uni- (UV) and multivariable (MV) analyses for SVR were performed using a com-
plete model (genotype, viral load, age, sex and previous PEG-IFN) [12] that also
included FT and biopsy. Logistic regression analyses, with SVR as the response
variable and key baseline and demographic variables as explanatory variables,
were performed to assess the effect of the prognostic factors on SVR rates. Step-
wise regression methods were used to build prediction models. In the modeling
FT was entered as a continuous variable and biopsy as METAVIR stages. SVR rates
were also summarized by baseline METAVIR ﬁbrosis score (F2, F3 and F4), esti-
mated both by FT and biopsy. The Armitage S trend test was used to compare
the proportion of patients who attained SVR among these patients. Number
Cruncher Statistical Software was used [24].
Diagnostic and prognostic value of ActiTest and SteatoTest
Both the degree of necroinﬂammation and steatosis were also evaluated using
validated biomarkers, ActiTest and SteatoTest, previously validated in naive
patients [9,10,16].
The predetermined following cutoffs of FT values were used for the corre-
sponding METAVIR stages: 60.27: F0; 60.48: F1; 60.58: F2; 60.74: F3;and
>0.74: F4.
Signiﬁcant activity was deﬁned as presumed grade A2/A3 (METAVIR scoring
system: moderate/severe necroinﬂammatory activity) according to the 0.52 lab-
oratory predetermined cutoff [3]. The predetermined following cutoffs of AT val-
ues were used for the corresponding METAVIR grades: 60.29: A0; 60.52: F1;
60.62: F2;and >0.62: A3.
Signiﬁcant steatosis was deﬁned as presumed stage S2/S3/S4 (steatosis
between 5% and 100%) according to the laboratory predetermined cutoff [16].Undetectable RNA
n = 506
SVR 58%
<2-log RNA drop
n = 43a
SVR 0%b
≥2-log RNA drop
n = 108
SVR 13%b
Treated 48 weeks
Fig. 1. Flow diagram of patients included in the therapeutic study and in the
diagnosis study.Results
Patient characteristics
In all, 2333 patients were screened, 2312 patients were enrolled
(treatment and safety population) and 1459 patients (diagnostic
population) had available baseline FT, biopsy and complete dataJournal of Hepatology 201to be included in the present study. Four patients were excluded
due to un-interpretable FT results (Fig. 1).
Baseline characteristics of the diagnostic population were
similar to the safety population (Table 1): 70% male; median
age 51 years; 28% with few ﬁbrous septa (METAVIR F2), 29% with
many septa (F3) and 43% with cirrhosis (F4) at biopsy; previous
relapses 29%; previous PEG-IFN regimen 41%; genotype 1 in
82%; and high (>6  105 IU/ml) baseline viral load (BVL) in 64%.
The median time difference between FT sampling and historical
biopsy was 161 days (95% CI 150–168).
Diagnostic value of FT
The accuracy of FT for the diagnosis of ﬁbrosis in the present pop-
ulation of non-responder patients was similar to that of previous
validations in treatment-naive patients for all the observed and
adjusted AUROCs, according to prevalence of stages or biopsy
length (Table 2) [3,23]. The unique test estimating all pairwise
performances using Obuchowski measure was signiﬁcant versus
random performance (Table 2). The mean biopsy length was sim-
ilar in the present study to that in the previously published inte-
grated database (13 mm vs 16 mm) [14]. The observed AUROCs
were 0.75 for the diagnosis between F2 and F4, 0.65 between
adjacent stages F2 and F3 and 0.62 between F3 and F4. These1 vol. 54 j 227–235 229
Table 1. Baseline Patient Characteristics of the ‘‘Safety’’ and ‘‘Diagnostic
Population’’.
Safety  
populationa
n = 2312 
Diagnostic  
population 
n = 1459 
Male, n (%) 1650 (71) 1015 (70)
Caucasian, n (%) 1932 (84) 
Mean age, y (SD) 49.2 (12.4) 50.9 (8.3) 
Fibrosis stage (METAVIR)
)2F(atpesweF 658 (29) 410 (28) 
)3F(atpesynaM 676 (29) 424 (29) 
)4F(sisohrriC 974 (42) 625 (43) 
Necroinflammatory 
activity (METAVIR) 
)0A(ytivitcaoN 157 (7) 92 (6) 
)1A(ytivitcalaminiM 1742 (75) 1107 (76) 
)71(542)71(983)2A(ytivitcaetaredoM
)3A(ytivitcaereveS 22 (1) 15 (1) 
Mean weight, kg 81.1 80.5  
Genotype, n (%) 
  1 1859 (80) 1203 (82) 
  2 75 (3) 47 (3) 
  3 294 (13) 168 (12) 
  4 68 (3) 37 (3) 
gnissiM 17 (1) 4 (<1) 
Viral load
lm/UI000,006 853 (37) 524 (36) 
  >600,000 IU/ml 1451 (63) 935 (64) 
  Missing 8 (<1) 0 (0) 
Previous combination 
therapy, n (%) 
IFN alfa + ribavirin 1425 (62) 857 (59) 
)14(206)73(568nirivabir+aflaNFI-GEP
)1(22yparehtnoitanibmocoN 0 (0) 
Previous response, n (%)
Nonresponse 1401 (61) 880 (60)
Relapse 647 (28) 424 (29)
Treatment failureb 264 (11) 155 (11)
aAll patients enrolled in the EPIC3 trial [12].
bThere was no signiﬁcant difference for the characteristics of patients between the
safety population and the diagnostic population.
Research ArticleObAUROCs were equivalent to AUROCs of 0.78–0.81 after stan-
dardization on DANA and to AUROCs of 0.72–0.82 after standard-
ization to biopsy length (Table 2). The AUROC for stage F4 vs F2F3
was 0.69 (95% CI 0.66–0.71), higher than random value
(p <0.0001).
Virologic response to treatment
Results were comparable to those observed in the overall popu-
lation [12]. One thousand four hundred and ﬁfty nine patients
received PEG-IFN alfa-2b 1.5 lg/kg/wk plus WBD ribavirin
(800–1400 mg/days) for 12–18 weeks; 506 (35%) had undetect-230 Journal of Hepatology 201able serum HCV-RNA at TW12 (TW12neg); 678 (46%) were trea-
ted for 48 weeks with 24 weeks’ follow-up. In the 1459 patients
enrolled (intention-to-treat population), the rate of SVR was
21% (312/1459). The rate of SVR was 58% among the 506 patients
who were TW12neg, 13% among 108 patients with detectable but
P2-log drop in viral load (all of whom had an HCV-RNA of
<750 IU/ml and the majority had <125 IU/ml) and 0% among 43
patients with less than 2-log drop (Fig. 1).
Prognostic value of baseline FT
Baseline ﬁbrosis stage estimated using FT had the same prognos-
tic value as that estimated using biopsy for SVR and for EVR.
As observed in the therapeutic population, ﬁve baseline fac-
tors were signiﬁcantly associated with SVR (Table 3A) and EVR
(Table 3B) in UV and MV analyses: ﬁbrosis stage estimated using
FT or biopsy, genotype 2/3, BVL, prior relapse and previous treat-
ment with non-PEG-IFN.12 Among patients who were TW12neg
(n = 506), only three factors remained highly predictive of SVR
by MV analysis: ﬁbrosis estimated with FT or by liver biopsy,
genotype 2/3 and BVL (Table 3C).
A graded decrease in SVR was observed among all patients
(n = 1459), as well as the subset with EVR (n = 506), as the META-
VIR ﬁbrosis score increased by FT or biopsy analysis. SVR
decreased in the diagnostic population from 40% to 15% (Armit-
age test S for trend = 78,554; p <0.00001) and from 75% to 52%
(S = 8391; p = 0.004) in the 12-week responder subset according
to FT score for ﬁbrosis and from 27% to 16% (S = 56,637;
p = 0.00002) and from 63% to 48% (S = 9224; p = 0.001) for liver
biopsy scoring of ﬁbrosis, respectively (Fig. 2). This trend was also
consistent across patients classiﬁed as F0 and F1 with FT (Fig. 2).
When discordance between baseline ﬁbrosis estimates was
entered as a covariate in the model, FT retained a signiﬁcant pre-
dictive value for EVR (odds ratio [OR] = 0.24; p = 0.009 without
signiﬁcance for discordant cases OR = 1.02, p = 0.93) and SVR
(OR = 0.13; p = 0.003); however, biopsy scoring had a weaker pre-
dictive value for EVR (OR = 0.83; p = 0.03 with signiﬁcant predic-
tive value for discordant cases OR = 1.67; p = 0.003); a similar
trend was observed for SVR and biopsy (OR = 0.67; p = 0.004 with
borderline signiﬁcance for discordant cases OR = 1.41; p = 0.10).
Discordant patients according to FT and biopsy ﬁbrosis estimates
A total of 292 patients (94 presumed F0 and 198 F1 with FT) were
suspected to be either false negative of FT or false positive of
biopsy (144 F2, 80 F3, and 68 F4 with biopsy).
Comparison between biopsy length, inﬂammatory scores, and
ALT levels for these 292 discordant patients versus the 1167 con-
cordant patients observed: lower METAVIR inﬂammatory score at
biopsy:1.03 (95%CI 0.99–1.09) vs 1.15 (1.12–1.18) (p = 0.001);
lower median ALT: 58 UI/L (52–63) vs 94 (91–97); there was
no signiﬁcant difference between biopsy length: median 13 mm
(12–14) vs 12 mm (12–12) respectively (p = 0.18).Diagnostic and prognostic value of baseline biomarkers of activity
and steatosis
The accuracy (AUROCs) of ActiTest for the diagnosis of activity
grades was signiﬁcant (p <0.001), but consistently lower in the1 vol. 54 j 227–235
Table 2. Diagnostic Value of FibroTest (AUROCs and Obuchowski measures) for the Diagnosis Between Each Fibrosis Stage Observed in the Present Study (Non-
responders) and in Previous Integrated Data (Naive Patients).
FibroTest vs. Biopsy 
Comparison Nonresponders  Controls, Naivee
F4 vs F2 
Number of patients 1035 376 
Observed AUROCa 0.75 (0.72-0.78) 0.75 (0.70-0.80) 
Standardized AUROCb 0.80 (0.77-0.83) 0.80 (0.75-0.85)
Adjusted on biopsy length AUROCc 0.82 (0.79-0.85) 0.82 (0.77-0.87) 
Weighted Obuchowski measured 0.71 (0.68-0.74) 0.84 (0.80-0.86) 
F3 vs F2 
Number of patients 834  364  
Observed AUROCa 0.65 (0.61-0.68) 0.63 (0.58-0.68) 
Standardized AUROCb 0.81 (0.77-0.85) 0.79 (0.74-0.84)
Adjusted on biopsy length AUROCc 0.76 (0.72-0.80) 0.73 (0.68-0.78) 
Weighted Obuchowski measure 0.59 (0.56-0.62) 0.63 (0.61-0.65)
F4 vs F3   
Number of patients 1049 234 
Observed AUROCa 0.62 (0.59-0.66) 0.65 (0.59-0.71) 
Standardized AUROCb 0.78 (0.75-0.81) 0.81 
Adjusted on biopsy length AUROCc 0.72 (0.69-0.75) 0.76 
Weighted Obuchowski measure 0.58 (0.55-0.61) 0.63 (0.61-0.65) 
All pairwise comparisons (Obuchowski measure) 0.63 (0.61-0.65) 0.70 (0.68-0.72) 
All AUROCs were signiﬁcant (p <0.001) versus random AUROC (0.50). There was no signiﬁcant difference between the AUROCs of non-responders and naive patients. There
were lower weighted Obuchowski measures for non-responders compared to controls.
aObserved area under the receiver-operating characteristics curves (AUROCs) and 95% conﬁdence interval.
bStandardized AUROC preventing spectrum bias for eventual comparisons between studies, corresponding to a standard difference of ﬁbrosis stage of 2.5 METAVIR unit
[20].
cGold standard–adjusted AUROC for the given biopsy length preventing the bias of considering biopsy as a gold standard calculated as the ratio between ObAUROC and
GsAUROC of 16-mm biopsy versus gold standard (0.82 for F3 vs. F4 and 0.86 for F2 vs. F3) [21].
dObuchowski measure takes into account the spectrum effect (weighted according to difference between stages) and the overall measure takes into account the multiple
testing.
eIntegrated database of naive patients with chronic hepatitis C [14].
JOURNAL OF HEPATOLOGYpresent study than in the integrated database of naive patients
(Supplementary ﬁle 1) [14]. The Spearman correlation coefﬁcient
between ActiTest and activity grade at biopsy was 0.17
(p <0.0001), with an obvious spectrum bias among patients with
low activity scores (A0/A1) and high activity scores (A2/A3), as
76% of patients had A1 and 17% had A2. Among 76 patients
who had a biopsy and ActiTest within 2 months of each other,
the AUROC of A2/A3 versus A0/A1 was 0.71 (95% conﬁdence
interval [CI], 0.54–0.83) versus 0.60 (95% CI, 0.56–0.64) for those
patients with two or more months between their liver biopsy and
ActiTest (p = 0.16). There was no prognostic value of METAVIR
activity grades either estimated using ActiTest or biopsy (data
not shown).
The accuracy (AUROC) of SteatoTest (n = 1415) for the diag-
nosis of S2/S3/S4 (steatosis between 5% to 100%; prevalence
40%) versus S0/S1 (steatosis less than 5%; prevalence 60%)
was 0.68 (95% CI, 0.65–0.71) (p <0.0001 versus AUC of 0.50).
This was lower than AUROCs observed in 171 HCV naive
patients, performed 40 days apart: 0.80 (95% CI, 0.74–0.86;
p = 0.02). The Spearman correlation coefﬁcient between Steato-
Test and steatosis grade at biopsy was 0.32 (p <0.0001). Among
76 patients who had a biopsy and SteatoTest less thanJournal of Hepatology 2012 months apart, the AUROC was 0.77 (95% CI, 0.64–0.85) versus
0.68 (95% CI, 0.65–0.71) among patients tested 2 months or
more apart (p = 0.12).
We observed a signiﬁcantly lower SVR in patients with steato-
sis using liver biopsy estimate or SteatoTest. The SVR was lower
in those with high steatosis (>10%; S2) graded by liver biopsy
(18.8% SVR; 106/564) compared to those with steatosis 610%
(23.9% SVR; 203/850; p = 0.02). Those with more hepatic steatosis
by SteatoTest (>0.57) had an SVR of 18.1% (95/525) compared to
SteatoTest <0.57 (24.1% SVR; 214/889; p = 0.009).Discussion
The results of this study illustrate both the diagnostic and prog-
nostic utility of liver injury biomarkers (FT, ActiTest and Steato-
Test) for clinicians and suggest that they could serve as a
possible alternative to liver biopsy in patients with CHC for
whom previous combination therapy failed. The diagnostic value
of FT [2,3], Actitest, [14], and SteatoTest [16] has already been
validated in patients naive to HCV treatment. In this study, FT
had the same prognostic value as liver biopsy for predicting the1 vol. 54 j 227–235 231
Table 3A. Prognostic value of FibroTest versus biopsy for early virologic response.
Factor 
Fibrosis stage 
tseTorbiF
  Biopsy 
Genotype 2/3 
Baseline viral load <log6
Prior relapse (77 missing) 
Previous non-PEG-IFN 
Univariate Odds Ratio 
n = 1459 Significance 
4.9 (2.9-8.1) <0.0001 
1.2 (1.1-1.4) 0.001 
11.5 (7.9-16.6) <0.0001 
1.9 (1.5-2.4)  <0.0001 
6.2 (4.8-8.0) <0.0001 
1.3 (1.05-1.6) 0.02 
Multivariate Odds Ratio 
n = 1304 Significance
4.2 (2.2-7.9) <0.0001 
1.3 (1.1-1.5) 0.001 
8.9 (5.8-13.6) <0.0001 
1.5 (1.2-2.0) 0.003 
6.5 (4.9-8.8) <0.0001 
2.0 (1.5-2.7) <0.0001 
Research Articlelikelihood of a SVR to treatment for hepatitis C as has been pre-
viously observed in naive patients [8–10].
Limitations
The main limitations of this study were the non-simultaneous
measurement of the biomarkers and biopsy, the FT was not
assessed in all included patients, and the length of biopsy sam-
ples was suboptimal.
There were no differences in demographic characteristics,
baseline clinical parameters and virologic responses between
the patients who had the measurements required to accurately
assess FT and thus be included in the present study, and of those
patients recruited to the EPIC3 retreatment study (Table 1).
The variability of FT and its components have been exten-
sively investigated. The assays for this study were centralized
in two CLIA laboratories (LabCorp, Raritan, NJ, USA and Covance,
Indianapolis, IN, USA) following the recommended pre-analytic
and analytic procedures [13–15]. Only four (3/1000) patients
were excluded because of a high-risk proﬁle of false positive or
false negative. The usual main confounders were observed:
hemolysis of the sample, acute inﬂammation and Gilbert syn-
drome [3,7,13,14].
One disadvantage of employing FT alone versus biopsy to
evaluate hepatic ﬁbrosis would be the possible inclusion of
patients with additional causes of liver disease (e.g., due to alco-
hol, nonalcoholic steatohepatitis, or hemochromatosis). However,
this risk is reduced because FT has the same diagnostic value in
the most common causes of liver diseases [3] and the same prog-
nostic value as biopsy in patients with chronic hepatitis B [25]
and alcoholic liver disease [26]. The diagnosis of necroinﬂamma-Table 3B. Prognostic value of FibroTest versus biopsy for sustained virologic respon
876=n
Factor 
Fibrosis stage 
tseTorbiF
  Biopsy 
Genotype 2/3 
Baseline viral load <log6
Prior relapse
Previous non-PEG-IFN 
Univariate Odds Ratio 
Significa
4.5 (2.2-9.0) 
1.5 (1.2-1.8) 
4.5 (3.1-6.6) 
1.7 (1.2-2.3)  
1.6 (1.1-2.2) 
1.4 (0.99-1.9) 
<0.0001
<0.0001
<0.0001
0.0009 
0.007 
0.06 
aFor 77 patients prior type of response (relapse or non-responder) was missing.
232 Journal of Hepatology 201tory activity grades is also possible with ActiTest9 [14], as are ste-
atosis grades using SteatoTest, both for viral or nonviral steatosis
[16]. Other biomarkers (HFE gene, transferrin saturation, mag-
netic resonance imaging) could also provide non-invasive possi-
ble alternatives to biopsy for the diagnosis of hemochromatosis
[27].
One limitation in the validation portion of this study was the
relatively long mean duration between biopsy and serum sam-
pling (161 days). This limitation relates to the use of historical
biopsies for studies, which minimized the invasiveness of this
trial. This delay between FT and biopsy could be a factor that
may explain the lower accuracy observed for AT for the diagnosis
of activity grade and for SteatoTest for the diagnosis of steatosis
grade in comparison with the accuracy observed in studies of
naive patients in which the median interval between biopsy
and FT was only 40 days [16]. These features of activity and ste-
atosis are less stable than the ﬁbrosis stage, and this hypothesis is
supported by the increase of ActiTest and SteatoTest AUROCs in
subpopulations with shorter intervals between biopsy and sero-
logic testing. Despite these limitations (also present for biopsy),
this was a unique opportunity to validate these biomarkers as
prognostic indicators of subsequent viral clearance in a large pop-
ulation of prior non-responders to antiviral therapy. They are
fewer validations of SteatoTest in patients with chronic hepatitis
C than for FT [3–11] and ActiTest, [3,9,10,28] and the SteatoTest
performance must be conﬁrmed by other studies.
Another limitation of this study is the relatively short length
of biopsy sample (16 mm) in comparison with the recommended
length of 25 mm [29]. But as most studies of liver biopsy per-
formed in large populations fail to achieve this optimal length
[22], it may be argued that using more reproducible serologicse.
n = 601ance 
Multivariate Odds Ratio 
Significance
5.0 (2.3-11.0)
1.6 (1.3-2.0) 
4.0 (2.6-6.0) 
1.6 (1.2-2.3) 
1.7 (1.1-2.4) 
1.6 (1.1-2.3) 
<0.0001
<0.0001
<0.0001
0.005 
0.007 
0.02 
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Table 3C. Prognostic value of FibroTest versus biopsy for sustained virologic response among patients with early virologic response.
Factor 
Fibrosis stage 
tseTorbiF
  Biopsy 
Genotype 2/3 
Baseline viral load <log6
Prior relapse
Previous non-PEG-IFN 
Univariate Odds Ratio 
Significance 
Multivariate Odds Ratio 
Significancen = 506 n = 444a
300.0)0.8-5.1(5.3 300.0)0.01-6.1(0.4
300.0)7.1-1.1(4.1 1.5 (1.2-1.9) 7000.0
3.0 (2.0-4.6) <0.0001 2.9 (1.8-4.5) <0.0001 
400.0)4.2-2.1(7.1 20.0)4.2-80.1(6.1
69.0)4.1-7.0(99.0 08.0)6.1-7.0(60.1
11.0)9.1-39.0(3.1 1.3 (0.8-2.0) 32.0
aFor 62 patients prior type of response (relapse or non-responder) was missing.
JOURNAL OF HEPATOLOGYestimates of liver injury achieve the same or better results with-
out the attendant risks of a liver biopsy.
Advantages of serologic markers
The main advantages of this study are the large population of
non-responder patients, the multicenter, multinational and pro-
spective nature of the population, and the centralized assessment
of histology. The analyses of this study were made with an inde-
pendent and blinded assessment of biomarkers, ﬁbrosis stage,
activity and steatosis grades. During the trial, all sera were pro-
spectively stored. In this study we were able to demonstrate
the reproducibility of FT’s accuracy for the diagnosis of ﬁbrosis
stage, the reproducibility of baseline FT for the prediction of
SVR and for the ﬁrst time the demonstration of the prognosticS = 78554
p <0.00001
S = 8391
p = 0.004
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Fig. 2. Sustained virologic response (SVR) rate according to baseline ﬁbrosis stage est
patients with undetectable HCV-RNA at 12 weeks (EVR). When estimated using bio
excluded from the overall study. When estimated using FibroTest the baseline ﬁbrosis sta
be either false negatives of the FibroTest or false positives of the biopsy. In the absence
among EVR) of patients classiﬁed as F0 by FT were signiﬁcantly higher than those class
suggest that they could be biopsy false positives.
Journal of Hepatology 201values of biomarkers for EVR as well as the prognostic value of
FT in patients with undetectable HCV-RNA at 12 weeks of
therapy.
One advantage of biomarkers compared to biopsy assessment
is that it enables to both evaluate liver disease severity and to
anticipate the treatment outcome in patients with contraindica-
tions to biopsy or those who refuse it. Additionally biomarkers
can be safely used to provide long-term follow-up of liver disease
severity without the constraint of repetition of an invasive proce-
dure. Patients are spared the risks associated with liver biopsy.
An important advantage already demonstrated in naive
patients [5,9,10] is that FT is at least as accurate as biopsy for pre-
dicting virologic response, either SVR or SVR among patients with
EVR. As with treatment-naive patients, baseline METAVIR ﬁbrosis
score estimated using biopsy or FT was the second strongestS = 56637
p = 0.00002
S = 9224
p = 0.001
27
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imated using either FibroTest or biopsy in overall diagnostic population and in
psy, patients with baseline stages F0 (no ﬁbrosis) and F1 (portal ﬁbrosis) were
ge was F0 and F1 in 94 and 198 patients, respectively. These discordant cases could
of a true gold standard, the fact that the virologic responses (either SVR or SVR
iﬁed F2 by biopsy (40% vs 27% for SVR, 75% vs 63% for SVR among EVR) strongly
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predictor, after genotype and before BVL, in the present study.
These data establish TW12 as a simple and effective point at
which to decide on retreatment with PEG-IFN alfa-2b/ribavirin
of patients who previously failed interferon alpha/ribavirin treat-
ment. After considering patient and disease factors, including
ﬁbrosis stage using FT, patients with HCV-RNA below the LLD
at TW12 – those with negative or near negative results – should
continue therapy (>50% chance of SVR), whereas others can be
spared further drug exposure because the likelihood of attaining
an SVR is low. Alternatively, these patients may consider long-
term low-dose maintenance therapy [12,30–33].
Although other studies [34,35] have shown that signiﬁcant
ﬁbrosis and cirrhosis are negative predictors of SVR, EPIC3 is
the ﬁrst large study to clearly demonstrate a graded decrease in
SVR rates as ﬁbrosis score progresses from F2 to F3 to F4 both
using biopsy and FT [12]. Furthermore, as suggested in previous
studies [32], it seems possible that FT could be even better than
short-length biopsy for the prediction of SVR [4,5,9]. In the pres-
ent study 302/1459 (20%) patients were classiﬁed at baseline as
F0 (n = 94) or F1 (n = 198) by FT and these same patients were
classiﬁed by biopsy as F2 or F3 or F4 by biopsy. As already dem-
onstrated these discordant cases could be either false negatives of
the FT or false positives of the biopsy [4,5,9]. In the absence of a
true gold standard, the fact that the virologic responses (either
SVR, EVR, or SVR among EVR) of patients classiﬁed as F0 by FT
were signiﬁcantly higher than of those classiﬁed as F2 by biopsy
(40% vs 27% for SVR, 54% vs 42% for EVR, 75% vs 63% for SVR
among EVR) strongly suggest that the liver biopsy scores were
incorrect. The multivariate analysis reinforced this hypothesis
as the knowledge of discordant cases signiﬁcantly increased the
prognostic value of ﬁbrosis staging using biopsy but not using FT.
Despite the smaller number of validations for ST, the present
study suggests that similar to ﬁndings in treatment-naive
patients, steatosis scored by SteatoTest is another predictor of
SVR (albeit less accurate) in previously non-responder patients.
However, the respective roles of metabolic and viral steatosis as
independent prognostic factors need further study [36].Conclusions
Biomarkers such as FibroTest can be used as a possible alterna-
tive to liver biopsy for ﬁbrosis staging and thus simplify the man-
agement of patients with CHC who failed their ﬁrst treatment. As
previously suggested in treatment-naive patients, these validated
biomarkers should also facilitate the design of trials in non-treat-
ment-naive patients [8,9]. They could also be used as surrogate
markers in trials evaluating the risk–beneﬁt of maintenance ther-
apy, without increasing the risk and the cost of repeated liver
biopsies but with an increase of power through repeated non-
invasive measures of biomarkers.Financial support
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